The effect of oral montelukast in controlling acute asthma attacks in childre

Phase 3

• Conditions: Acute asthma attack.; Severe persistent asthma; J45.50

• Registration Number: IRCT20220508054776N1
• Lead Sponsor: Ghoum University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 13 November 2023

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 90

Inclusion Criteria

Children aged 5-13 years
Children with an acute asthma attack

Exclusion Criteria

Parents' lack of consent to participate in the study
The child's heart, lung, and metabolic diseases
Children under 5 years old and over 13 years old
History of anti-leukotriene use in the last two weeks
Children who need intubation for treatment

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
PEF. Timepoint: PEF measurement on arrival and 6 hours later. Method of measurement: Picoflowmeter device.;The effect of adding oral montelukast to standard treatment on patient's blood oxygen. Timepoint: Upon arrival and 6 hours later. Method of measurement: with pulse oximeter.

Secondary Outcome Measures

Name	Time	Method
Effect of adding oral montelukast to standard treatment on vital signs. Timepoint: Upon arrival and 6 hours later. Method of measurement: Examination of the patient by a doctor.;Effect of adding oral montelukast to standard treatment on respiratory distress. Timepoint: Upon arrival and 6 hours later. Method of measurement: Examination of the patient by a doctor.